Stent Data Affects Diabetic Device Markets, Report Says

The U.S. market for diabetic vascular disease devices is valued at more than $1.25 billion this year, but future growth will be limited by negative clinical studies surrounding coronary drug-eluting stents and more aggressive medical management, according to a recent report from Millennium Research Group (MRG).

This market comprises devices for treating diabetic coronary revascularization, diabetic nephropathy and diabetic neuropathy.

The report, “U.S. markets for diabetic vascular disease treatment devices 2007,” said the market has been driven by diabetic population growth, increased screening and detection of vascular complications and positive clinical data on endovascular treatments.

Of the overall diabetic vascular disease devices market, the diabetic coronary revascularization market makes up almost 85 percent, at slightly more than $1 billion in 2007. It comprises coronary stents, percutaneous coronary transluminal angioplasty balloon catheters and coronary atherectomy devices.

According to MRG, growth in this area will improve following positive clinical data on the use of drug-eluting stents in diabetes patients, as well as the expected release of next-generation drug-eluting stents, “which have shown promising clinical data with respect to late-stent thrombosis.” Additionally, coronary artery bypass surgery procedures will continue to be cannibalized by increased adoption of minimally invasive endovascular approaches, the report said.

Another segment, the diabetic nephropathy market, will garner more than $100 million in revenue by 2012, the report said. This market, comprising dialysis catheters, percutaneous transluminal angioplasty balloon catheters, thrombectomy devices and synthetic arteriovenous grafts, will be driven by an increase of end-stage renal disease, increased screening measures for renal disease in diabetic patients and growth in arteriovenous access management procedures, according to the report. MRG predicted that market growth will be limited by declining synthetic arteriovenous grafts.

Finally, the diabetic neuropathy market, comprising peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, peripheral atherectomy devices and synthetic bypass grafts, has been driven by elderly diabetic population growth, increased screening for neuropathy and peripheral vascular disease, and advances in lower extremity revascularization procedures, MRG said.

Over the forecast period, improvements to endovascular interactions, combined with reduced recovery times, will allow endovascular interventions to penetrate the market. However, market growth will be limited by recent negative clinical data concerning coronary drug-eluting stents, which is expected to delay market entry of peripheral drug-eluting stents, the report said. — April Astor